Publication | Open Access

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

MedicineMelanomaImmunologyClinical TrialsAdjuvant VemurafenibBrafv600 Mutation-positive MelanomaDermatologyOncologyRadiation OncologyNovel TherapyMolecular OncologyPhase 3Health Sciences